Figure 1.
Progression-free survival (A) and incidence of local-regional failures between patients treated with cCRT alone and cCRT plus durvalumab (B).
Progression-free survival (A) and incidence of local-regional failures between patients treated with cCRT alone and cCRT plus durvalumab (B).